Stealth BioTherapeutics Plans Exit After FDA Sends Mixed Signals
Stealth BioTherapeutics, the biotech equivalent of a cautious cat, is prepping to shut down after receiving what it called 'conflicting' signals from the FDA. It’s like getting a yes, no, maybe so, and ¯\_(ツ)_/¯ all in one letter. Developing a rare disease drug isn’t for the faint of heart, but apparently trying to decode FDA feedback is a full-contact sport. The company said it's making 'contingency plans to close,' proving sometimes the biggest rare disease is surviving bureaucracy without a sequel to your disaster.
Share the Story
(1 of 3)When the FDA's feedback is so confusing even a biotech drug pitcher gives up and says 'plot twist: closing time.' Rare disease drugs? More like rare clarity.
Stealth BioTherapeutics just experienced the classic FDA mixed signal — like getting ghosted on a text but with your company’s life. 'It’s not you, it’s the ambiguous regulatory dance.'
Trying to get FDA approval from Stealth BioTherapeutics must feel like sending a message in a bottle tossed into a bureaucratic Bermuda Triangle—where rare diseases go to wait for clarity that never arrives.
Source: Statnews | Published: 8/5/2025 | Author: Ed Silverman
More Articles in Health
Microsoft Finally Lets Windows 11 Fans Stop Pretending to Use ViVeTool
Epstein Survivors Declare 'Done' While Melania Passes the Buck Faster Than a Baton
VP Vance Heads to Pakistan to Broker Peace, Backed by Kushner and Trump’s Threats
Competitive Swimmer Drops 60 Pounds Using Costco Snacks, No Sweat Required
Telehealth Startup Outsources Doctors to AI and Angolan Phone Lines
Widow Turns Frozen Sperm Time Capsule Into Baby After 10-Year Hiatus
OpenAI CEO Temporarily Downgrades from AI Overlord to Human POTS Patient
Woman Quits Job at 38 to Audit Diaper Changing as Full-Time Gig
